Company news

Hyloris Pharmaceuticals SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Consolidated 2026 Half-Year Report: Hyloris Delivers 56% Revenue Growth and Its Lowest Half-Year Net Loss Since IPO, Advances Its Mavericks, Core Drivers and Promising Seeds

September 28, 2026

Hyloris Pharmaceuticals: Regulated Information Hyloris’ Annual General Shareholders Meeting on June 9, 2026 ENGLISH VERSION

May 8, 2026

Hyloris Pharmaceuticals: Regulated Information Hyloris releases Annual Report 2025 ENGLISH VERSION

April 30, 2026

Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones

March 26, 2026

Hyloris Pharmaceuticals: Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension ENGLISH VERSION

February 19, 2026

Hyloris Pharmaceuticals Provides Update on FDA Review of Valacyclovir for Oral Suspension

February 19, 2026

Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdings

February 2, 2026

Hyloris Pharmaceuticals Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets

January 19, 2026

Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed

December 30, 2025

Hyloris Pharmaceuticals: Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. ENGLISH VERSION

December 29, 2025

Hyloris Pharmaceuticals Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder

December 11, 2025

Hyloris Pharmaceuticals: Board of Directors appoints Stijn Van Rompay as CEO

November 19, 2025

Hyloris Pharmaceuticals Announces Positive Clinical Study Results for IV Aspirin

November 14, 2025

Inside Information Hyloris and Orion Partner to Bring Tranexamic Acid RTU to Key European Markets ENGLISH VERSION

October 28, 2025

Hyloris Pharmaceuticals Announces Partnership with Grand Life Sciences Group for HY-094 in China

October 27, 2025

Consolidated 2025 Half-Year Results and Outlook: Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position

September 25, 2025

Decks

The 5 newest of 30 decks. Every deck is listed under its year.